Relationship Between Circulating Tumor Cells and Tumor Response in Colorectal Cancer Patients Treated with Chemotherapy: a Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Dec 19

PMID 25519477

Citations 44

Authors

Xuanzhang Huang

Peng Gao

Yongxi Song

Jingxu Sun

Xiaowan Chen

Junhua Zhao

Jing Liu

Huimian Xu

Zhenning Wang

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic value of circulating tumor cells (CTCs) in colorectal cancer (CRC) patients and their value in predicting tumor response to chemotherapy are controversial. The aim of this meta-analysis was to assess the prognostic and predictive value of CTCs in CRC patients treated with chemotherapy.

Methods: A comprehensive literature search for relevant studies was conducted in PubMed, Embase, the Cochrane Database, the Science Citation Index and the Ovid Database, and the reference lists of relevant studies were also perused for other relevant studies (up to April, 2014). Using the random-effects model in Stata software, version 12.0, the meta-analysis was performed using odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as effect measures. Subgroup and sensitivity analyses were also performed.

Results: Thirteen eligible studies were included. Our meta-analysis indicated that the disease control rate was significantly higher in CRC patients with CTC-low compared with CTC-high (RR = 1.354, 95% CI [1.002-1.830], p = 0.048). CRC patients in the CTC-high group were significantly associated with poor progression-free survival (PFS; HR = 2.500, 95% CI [1.746-3.580], p < 0.001) and poor overall survival (OS; HR = 2.856, 95% CI [1.959-4.164], p < 0.001). Patients who converted from CTC-low to CTC-high or who were persistently CTC-high had a worse disease progression (OR = 27.088, 95% CI [4.960-147.919], p < 0.001), PFS (HR = 2.095, 95% CI [1.105-3.969], p = 0.023) and OS (HR = 3.604, 95% CI [2.096-6.197], p < 0.001) than patients who converted from CTC-high to CTC-low.

Conclusions: Our meta-analysis indicates that CTCs are associated with prognosis in CRC patients treated with chemotherapy. Moreover, CTCs could provide additional prognostic information to tumor radiographic imaging and might be used as a surrogate and novel predictive marker for the response to chemotherapy.

Citing Articles

Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas.

Barber H, Perks C, Kurian K Front Neurol. 2024; 15:1358531.

PMID: 38481938 PMC: 10932969. DOI: 10.3389/fneur.2024.1358531.

Chemically-Modified Sepharose 6B Beads for Collection of Circulating Tumor Cells.

Chen H, Zhang Y, Ma X, Zhou B, Liu Z Biomolecules. 2023; 13(7).

PMID: 37509107 PMC: 10377418. DOI: 10.3390/biom13071071.

Predictive value of circulating tumor cell counts during the treatment of cancer: interactions with the blood microenvironment.

Yang L, Zeng X, Yang G, Li Y, Pan Y Int J Clin Oncol. 2023; 28(8):1011-1022.

PMID: 37243775 DOI: 10.1007/s10147-023-02355-5.

Simple Detection and Culture of Circulating Tumor Cells from Colorectal Cancer Patients Using Poly(2-Methoxyethyl Acrylate)-Coated Plates.

Nomura M, Yokoyama Y, Yoshimura D, Minagawa Y, Yamamoto A, Tanaka Y Int J Mol Sci. 2023; 24(4).

PMID: 36835361 PMC: 9959032. DOI: 10.3390/ijms24043949.

Single-Cell Analysis of Circulating Tumor Cells from Patients with Colorectal Cancer Captured with a Dielectrophoresis-Based Micropore System.

Nomura M, Miyake Y, Inoue A, Yokoyama Y, Noda N, Kouda S Biomedicines. 2023; 11(1).

PMID: 36672711 PMC: 9855761. DOI: 10.3390/biomedicines11010203.

References

Seymour M, Maughan T, Ledermann J, Topham C, James R, Gwyther S . Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370(9582):143-152. DOI: 10.1016/S0140-6736(07)61087-3. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Molnar B, Sipos F, Galamb O, Tulassay Z . Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis. 2004; 21(4):320-5. DOI: 10.1159/000075355. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

Schmid C, Stark P, Berlin J, Landais P, Lau J . Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol. 2004; 57(7):683-97. DOI: 10.1016/j.jclinepi.2003.12.001. View

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Oye R, Shapiro M . Reporting results from chemotherapy trials. Does response make a difference in patient survival?. JAMA. 1984; 252(19):2722-5. View

10.

Escudier B, Eisen T, Stadler W, Szczylik C, Oudard S, Siebels M . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-34. DOI: 10.1056/NEJMoa060655. View

11.

Kuboki Y, Matsusaka S, Minowa S, Shibata H, Suenaga M, Shinozaki E . Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013; 33(9):3905-10. View

12.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

13.

Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R . KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer. 2012; 107(4):626-31. PMC: 3419946. DOI: 10.1038/bjc.2012.275. View

14.

Staritz P, Kienle P, Koch M, Benner A, Knebel Doeberitz M, Rudi J . Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients. J Exp Clin Cancer Res. 2005; 23(4):633-9. View

15.

Yen L, Yeh Y, Chen C, Wang H, Tsai H, Lu C . Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2009; 15(13):4508-13. DOI: 10.1158/1078-0432.CCR-08-3179. View

16.

Vigano L, Capussotti L, De Rosa G, de Saussure W, Mentha G, Rubbia-Brandt L . Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013; 258(5):731-40. DOI: 10.1097/SLA.0b013e3182a6183e. View

17.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

18.

de Albuquerque A, Kubisch I, Stolzel U, Ernst D, Boese-Landgraf J, Breier G . Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med. 2012; 10:222. PMC: 3508882. DOI: 10.1186/1479-5876-10-222. View

19.

Konigsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M . Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett. 2010; 293(1):117-23. DOI: 10.1016/j.canlet.2010.01.003. View

20.

van Houwelingen H, Arends L, Stijnen T . Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002; 21(4):589-624. DOI: 10.1002/sim.1040. View